Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-101, which is being developed in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients in first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021.
CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to synergize with antibody therapeutics Phase 1/2a clinical trial will evaluate the safety and preliminary efficacy of CYNK-101...
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021.
FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced financial results for the third...
Florham Park, N.J. & San Diego, C.A., September 20, 2021: Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, and Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq:...
Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25 years’ experience developing life-changing cellular medicines FLORHAM PARK, N.J., – September 15, 2021 — Celularity...
Secured funding of approximately $138 million through merger and private placement investment in public equity (PIPE) financing Expanded Phase 1 clinical trial to include difficult-to-treat patient population Established multiple strategic...
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytics) and Celularity’s CD19 targeting chimeric antigen receptor (CAR) placental-derived T-cell therapy, CYCART-19 Nonclinical in...
Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol “CELU” on July 19, 2021 Clinical pipeline includes multiple clinical...
The Brain Mapping Foundation and the Society for Brain Mapping and Therapeutics to celebrate this trailblazing scientist, surgeon, visionary leader and serial entrepreneur at the 18th Annual Gathering for the...
Arthrex to receive exclusive rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics and sport medicine in the United States FLORHAM PARK, NJ, and NAPLES, FL, July 01,...
No dose limiting toxicity to date with outpatient administration of three doses (Days 0, 7 and 14) at total dose levels of 1.8, 3.6, and 5.4 Billion CYNK-001 cells, respectively...
Pharmaceutical industry veteran brings more than 20 years of business and technical operations experience across various commercial and development products FLORHAM PARK, N.J., – May 20, 2021 — Celularity Inc. (“Celularity”),...
Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities Partnership includes equity investment by Palantir in Celularity...
NEW YORK, April 16, 2021 /PRNewswire/ — On April 14, 2021, GX Acquisition Corp. (“GX”) (NASDAQ: “GXGX”), provided information regarding a proposal to amend GX’s amended and restated certificate of incorporation (the “Charter”) to...
FLORHAM PARK, N.J., April 13, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies...
Presentations to showcase updates related to multiple Celularity programs in immuno-oncology and infectious disease FLORHAM PARK, N.J., April 09, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company,...
FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies...
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition
Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer
Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
Celularity Appoints Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President
Celularity Reports Second Quarter 2021 Financial Results
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus – Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
Celularity Founder, Chairman and Chief Executive Officer, Robert J. Hariri, M.D., Ph.D., Dually Awarded for Pioneering Contributions in Medicine and Leadership
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products
Celularity Announces Expansion of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Phase 1 Trial in Patients with Acute Myeloid Leukemia
Celularity Appoints Bradley Glover, Ph.D. as Executive Vice President and Chief Technology Officer
Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies
GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination
Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas
Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme